Molecular biology of human immunodeficiency virus type-1
S Joshi, RL Joshi - Transfusion science, 1996 - Elsevier
Tremendous progress has been made in our understanding of the multiplication and
pathogenesis of the human immunodeficiency virus, the causative agent of acquired …
pathogenesis of the human immunodeficiency virus, the causative agent of acquired …
[PDF][PDF] Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies
B Lamothe, S Joshi - Front Biosci, 2000 - researchgate.net
Introduction 2.1. HIV-1 molecular biology 2.1. 1. Genetic map of HIV-1 RNA 2.1. 2. HIV-1 life
cycle 2.2. Interfering RNAs 2.2. 1. Antisense RNAs 2.2. 2. Sense RNAs 2.2. 3. Ribozymes …
cycle 2.2. Interfering RNAs 2.2. 1. Antisense RNAs 2.2. 2. Sense RNAs 2.2. 3. Ribozymes …
Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication
SF Ding, J Noronha, S Joshi - Nucleic acids research, 1998 - academic.oup.com
Retroviral vectors were engineered to express either sense (MoTiN-TRΨ e+) or sense and
antisense (MoTN-TRΨ e+/−) RNAs containing the human immunodeficiency virus type-1 …
antisense (MoTN-TRΨ e+/−) RNAs containing the human immunodeficiency virus type-1 …
Targeted RNases: a feasibility study for use in HIV gene therapy
S Singwi, A Ramezani, SF Ding, S Joshi - Gene therapy, 1999 - nature.com
A targeted RNase would be ideal for gene therapy of several acquired and inherited
disorders. Such an RNase may be engineered to contain a ribonucleolytic domain and a …
disorders. Such an RNase may be engineered to contain a ribonucleolytic domain and a …